Radiant Pharmaceuticals (NYSE AMEX: RPC) CEO InterviewRadiant Pharmaceuticals (NYSE AMEX: RPC) CEO InterviewThis interview has expired. Special deals for our readers Be a more profitable investor: Get an Equifax 3-in-1 Credit Report Now! Why are you still paying too much with Schwab, and and E-trade?? Step up to the #1 discount broker: TradeKing. Invest Smarter! Get 4 Bonus Weeks of Investor’s Business Daily Digital Edition! LifeLock is the only Identity Theft Prevention Solution backed by a one-million dollar guarantee!Click here to get a 10% discount. Get FICO Score Watch Now! Click here to get access to powerful investing tools only available at Investor’s Business Daily. Get a free look at Jim Cramer’s Action Alerts PLUS portfolio. Click here Radiant Pharmaceuticals Radient Pharmaceuticals Corporation, formerly AMDL, Inc., is a vertically integrated specialty pharmaceutical company with three distinct business divisions that include In-Vitro diagnostics, China-based pharmaceutical manufacturing and distribution and cancer therapeutics. These business units focus on the development, manufacturing, distribution and sales of medical diagnostic products, generic pharmaceuticals, nutritional supplements, and cosmetics in the United States, China, Korea, Taiwan and other markets. The Company also has been engaged in the commercial development of and the obtaining of various governmental regulatory approvals for the marketing of its diagnostic tumor-marker test kit (DR-70) to detect the presence of multiple types of cancer. The Company operates in China through its wholly owned subsidiary, Jade Pharmaceutical Inc. (JPI). Leave a Reply |
|
WSR Recommends |
||
| Special Deal for Our Readers (That’s You!) | Jim Cramer: The Clown That Makes You Money | Get Rich with Fibonacci. Learn How to Use Fibonacci Analysis to Trade Better. |
